Tumor necrosis factor α inhibitors (anti-TNF) have improved treatment of several complex diseases, including Crohn’s disease (CD). However, the effect varies and approximately one-third of the patients do not respond. Since blood parameters as well as genetic factors have shown a great potential to predict response during treatment, the aim of the study was to evaluate response to anti-TNF treatment with adalimumab (ADA) between genes HFE and TF and haematological parameters in Slovenian refractory CD patients. Single nucleotide polymorphisms (SNPs) rs1799852 in gene TF and rs2071303 in gene HFE were genotyped in 68 refractory CD patients for which response has been measured using inflammatory bowel disease questionnaire (IBDQ) index. Haematological parameters and IBDQ index were determined before therapy and after 4, 12, 20 and 30 weeks. We found novel strong association between SNP rs2071303 in gene HFE and response to ADA treatment, particularly patients with G allele comparing to A allele had better response after 20 weeks (p = 0.008). Further, we found strong association between transferrin level at baseline and treatment response after 12, 20 and 30 weeks, where average transferrin level before therapy was lower in responders (2.38 g/L) compared to non-responders (2.89 g/L, p = 0.005). Association was found between transferrin level in week 30 and SNP rs1799852 (p = 0.023), and between MCHC level before treatment and SNP rs2071303 (p = 0.007). Our results suggest that SNP in gene HFE as well as haematological markers serve as promising prognostic markers of response to anti-TNF treatment in CD patients.
Anti-TNF Adalimumab Transferrin HFE gene TF gene
This is a preview of subscription content, log in to check access.
Feder JN et al (1998) The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 95:1472–1477CrossRefPubMedPubMedCentralGoogle Scholar
Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C (1989) A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 96:804–810CrossRefPubMedGoogle Scholar
Hetland ML et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO Registry. Arthritis Rheum 62:22–32. doi:10.1002/art.27227CrossRefPubMedGoogle Scholar
Hlavaty T, Persoons P, Vermeire S, Ferrante M, Pierik M, van Assche G, Rutgeerts P (2006) Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn’s disease. Inflamm Bowel Dis 12:199–204CrossRefPubMedGoogle Scholar
Khusainova RI, Khusnutdinova NN, Litvinov SS, Khusnutdinova EK (2013) Analysis of H63D mutation in hemochromatosis (HFE) gene in populations of central Eurasia. Genetika 49:269–278PubMedGoogle Scholar
Koder S, Repnik K, Ferkolj I, Pernat C, Skok P, Weersma RK, Potočnik U (2015) Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn’s disease patients. Pharmacogenomics 16:191–204. doi:10.2217/pgs.14.172CrossRefPubMedGoogle Scholar
Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ (2004) Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol Suppl 69:3–8PubMedGoogle Scholar
Moczulski DK, Grzeszczak W, Gawlik B (2001) Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care 24:1187–1191CrossRefPubMedGoogle Scholar
Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD (2002) Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 100:474–482. doi:10.1182/blood-2002-01-0136CrossRefPubMedGoogle Scholar
Parkkila S et al (1997) Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc Natl Acad Sci USA 94:2534–2539CrossRefPubMedPubMedCentralGoogle Scholar
Trinder MW, Lawrance IC (2009) Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 24:1252–1257CrossRefPubMedGoogle Scholar
Waheed A et al (1997) Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA 94:12384–12389CrossRefPubMedPubMedCentralGoogle Scholar
Zorzi F et al (2012) Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study. Aliment Pharmacol Ther 35:1397–1407CrossRefPubMedGoogle Scholar